A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Author:

Martin Thomas1,Baz Rachid2,Benson Don M.3,Lendvai Nikoletta45,Wolf Jeffrey1,Munster Pamela1,Lesokhin Alexander M.45,Wack Claudine6,Charpentier Eric7,Campana Frank7,Vij Ravi8

Affiliation:

1. UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA;

2. Moffitt Cancer Center, Tampa, FL;

3. Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;

4. Memorial Sloan Kettering Cancer Center, New York, NY;

5. Weill Department of Medicine, Weill Medical College of Cornell University, New York, NY;

6. Sanofi R&D, Alfortville, France;

7. Sanofi Oncology, Cambridge, MA; and

8. Section of Bone Marrow Transplantation & Leukemia, Division of Oncology, Department of Medicine, Washington University, St. Louis, MO

Abstract

Key Points Isatuximab (anti-CD38 monoclonal antibody) given with lenalidomide/ dexamethasone is active in heavily pretreated relapsed/refractory myeloma Overall, the safety profile of this combination is similar to the characteristic safety profiles of the individual agents.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 149 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3